The Global Stem Cell Therapy Market is projected to reach USD 18.9 billion in 2024 which is further anticipated to reach USD 54.7 billion by 2033 at a CAGR of 12.6%. The global stem cell therapy ...

2024 — Gut microbiome composition during pregnancy has long-term effects on offspring stem cell growth and development, researchers report. Treating pregnant mice with a common gut microbe ...

Over the last few decades, one such experimental treatment known as hematopoietic stem cell transplantation (HSCT) has been at the forefront of progressive MS research. HSCT attempts to reset the ...

Stem Cell Transplant A stem cell transplant (also known as a bone marrow transplant) is sometimes used to treat lymphoma, including B-cell lymphoma, among patients who are in remission or have a ...

Sep. 9, 2024 — Scientists developed a highly promising gene therapy to treat glaucoma -- a debilitating eye condition that can lead to complete vision loss, and which affects around 80 million ...

A team from Sheffield Teaching Hospitals NHS Foundation Trust led by two University of Sheffield Honorary Professors, are pioneering a breakthrough treatment in the UK for multiple sclerosis ... The ...

An alternative treatment paradigm ... from the glaucoma insult(s) to retinal ganglion cells. It has the potential to prevent retinal ganglion cell death independently of the particular factors ...

The ELIOS system offers a non-thermal, tissue-friendly laser-based approach, enhancing glaucoma treatment options. Combining ELIOS with cataract surgery could streamline care and improve patient ...

It requires prompt treatment and can be vision-threatening. Neovascular glaucoma develops when new blood vessels form over your iris and the area where fluid usually drains from your eye.

None are truly reflective of human glaucoma. Although there are a plethora of candidate neuroprotective agents identified from experimental and animal settings, only a handful have been translated ...

Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M.

Elios’ version offers a tissue-friendly, precision, non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma. The company currently offers the CE-marked technology in ...